Inflammation a factor in almost all diseases.
Yes, inflammation is a component of most CNS diseases. In fact, 21st-century medical science has come to the conclusion that inflammation, in one form or another, is involved with the vast majority of diseases and conditions.
Whether or not Anavex molecules might rather directly control or suppress such inflammation is unknown to me. I don't recall any such outcomes or references in the good number of Anavex technical papers I have perused.
That's not to claim any Anavex inflammation inefficacy; merely to state I've don't recall any references to the matter.
This does raise the question, however, what new, other diseases and conditions might Anavex molecules treat? Some time ago, the only target disease I was aware of was Alzeimer's. Now, Rett Syndrome is a prime target, closely followed by Parkinson's and other CNS diseases.
We've already conjectured on how Anavex 2-73 might well prove to be a remarkably safe and effective treatment for insomnia (with strong supportive evidence in the Australian trial).
In the Anavex pipeline webpage, there are indications or conjectures that Anavex molecules will treat cardiovascular conditions, psychiatric conditions, and cancers.
The spectrum of Anavex efficacies is yet unknown, but clearly wide.
With a lengthy, large-n Phase 3 Alzheimer's trial (later this year) all sorts of non-target, incidentally good outcomes may be discovered beyond just Alzheimer's symptoms (as were the insomnia results in the P1/P2 Australian trial).
